Literature DB >> 12390300

Reduced [125I]-Bolton Hunter substance P binding (NK1 receptors) in the basal forebrain nuclei of aged rats.

Dominic P Geraghty1, Christine M Maguire.   

Abstract

1. Quantitative autoradiography and homogenate radioligand binding of [125I]-Bolton Hunter substance P ([125I]-BHSP) were used to compare brain NK1 receptors in young (2 months) and aged (18-20 months) rats. 2. The autoradiographic distribution and density of [125I]-BHSP binding sites was similar in all cortical regions of young and aged rats. In contrast, the density of [125I]-BHSP binding sites was significantly (P < 0.05) lower in the basal forebrain nuclei (intermediate part of the lateral septal nuclei, medial septal nucleus and horizontal and vertical nuclei of the diagonal band) of aged rats. In all other brain regions examined, binding densities were almost identical in young and aged rats. 3. Because a population of NK1 receptors ([125I]-BHSP binding sites) in the basal forebrain nuclei is associated with cholinergic neurons, the decrease in NK1 receptors in aged rats may reflect degeneration of cholinergic neurons and contribute to the motor and cognitive deficiencies that occur with ageing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390300     DOI: 10.1046/j.1440-1681.2002.03781.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  2 in total

1.  Tacr1 gene variation and neurokinin 1 receptor expression is associated with antagonist efficacy in genetically selected alcohol-preferring rats.

Authors:  Jesse R Schank; Jenica D Tapocik; Estelle Barbier; Ruslan Damadzic; Robert L Eskay; Hui Sun; Kelly E Rowe; Courtney E King; Mengdi Yao; Meghan E Flanigan; Matthew G Solomon; Camilla Karlsson; Kejun Cheng; Kenner C Rice; Markus Heilig
Journal:  Biol Psychiatry       Date:  2013-02-16       Impact factor: 13.382

Review 2.  The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.

Authors:  Agnieszka Majkowska-Pilip; Paweł Krzysztof Halik; Ewa Gniazdowska
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.